ClinicalTrials.gg
CompletedNCT02107898Updated Oct 4, 2016Results posted

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

A Phase 3 interventional study of Placebo (for alirocumab) and Alirocumab in Hypercholesterolemia, sponsored by Sanofi. Completed at 32 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-10-04.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
17th of 43
216 · median 107
Started
2014
the only one that year
Phase 3
20 of 43
none open now
Registered
27th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 17th largest by enrollment, is the only one that started in 2014, is one of 20 in phase 3, and was the 27th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin therapy with or without other lipid modifying therapy in comparison with placebo after 24 weeks of treatment in heterozygous familial hypercholesterolemia (HeFH) or high cardiovascular risk participants with hypercholesterolemia.

Secondary Objectives:

  • To evaluate the effect of alirocumab in comparison with placebo on LDL-C after 12 weeks of treatment.
  • To evaluate the effect of alirocumab on other lipid parameters.
  • To evaluate the long-term effect of alirocumab in comparison with placebo on LDL-C after 52 weeks of treatment.
  • To evaluate the safety and tolerability of alirocumab.
  • To evaluate the development of anti-alirocumab antibodies.
  • To evaluate the pharmacokinetics of alirocumab.
Read the detailed description

Total duration per participant of approximately 63 weeks (14 months) (screening: 3 weeks, double-blind treatment period: 52 weeks, and follow-up period: 8 weeks).

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia who were not adequately controlled with a stable daily dose of statin with or without other lipid modifying therapy, at stable dose prior to the screening visit (Week -3).

Exclusion criteria

Exclusion criteria:

  1. LDL-C \<100 mg/dL (\<2.59 mmol/L) at the screening visit in participants with heterozygous familial hypercholesterolemia or in participants with non-familial hypercholesterolemia who had a history of documented coronary heart disease as described in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
  2. LDL-C \<120 mg/dL (\<3.10 mmol/L) at the screening visit in participants with non-familial hypercholesterolemia who had a history of documented diseases or other risk factors as categorized in primary prevention category III as described in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
  3. Not on a stable daily dose of lipid modifying therapy (including statin) within 4 weeks prior to the screening visit or between screening and randomization visits.
  4. Age \<20 years at the screening visit.

The above information is not intended to contain all considerations relevant to a participants' potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
216 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).

    Drug: Placebo (for alirocumab) · Drug: Lipid-Modifying Therapy (LMT)

  • Experimental
    Alirocumab 75 mg/Up to 150 mg Q2W

    Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e. * ≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD) * ≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III

    Drug: Alirocumab · Drug: Lipid-Modifying Therapy (LMT)

Interventions

  • DrugPlacebo (for alirocumab)

    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

  • Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

    Also known as: SAR236553, REGN727, Praluent

  • Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)

    Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  4. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From baseline to Week 24

  5. Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  6. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  7. Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 24

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  9. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  11. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  12. Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis

    Calculated LDL-C goal was defined as: * \<100 mg/dL (2.59 mmol/L) for heFH or non-FH participants who had a history of documented congestive heart disease (CHD), or * \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases (ischemic stroke, peripheral artery disease, chronic kidney disease or diabetes) or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in imputation model.

    Time frame: Up to Week 24

  13. Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

    Time frame: Up to Week 24

  14. Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model.

    Time frame: From Baseline to Week 24

  15. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  16. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  17. Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  18. Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  19. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 24

  20. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  21. Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

Other outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

    Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  2. Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 52 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

07

Results

Posted Jan 29, 2016

Participant flow

The study was conducted at 31 centers in Japan. A total of 319 participants were screened between March 2014 and July 2014, 103 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Started72144
Treated72143
Completed66132
Not completed612
Withdrew: Adverse event47
Withdrew: Poor compliance to protocol01
Withdrew: Participant moved02
Withdrew: Consent withdrawn by participant21
Withdrew: Randomized but not treated01

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)

Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)1.6 ± 1.8-62.5 ± 1.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -64.1 · 95% CI -68.5 to -59.8Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis1.7 ± 1.7-63.7 ± 1.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -65.3 · 95% CI -69.4 to -61.3Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis-2.7 ± 1.6-64.2 ± 1.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -61.5 · 95% CI -65.3 to -57.7Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis-2.8 ± 1.5-64.8 ± 1.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -62.1 · 95% CI -65.8 to -58.3Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis-1.6 ± 1.7-55.0 ± 1.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -53.3 · 95% CI -57.5 to -49.1Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis-2.1 ± 1.7-55.9 ± 1.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -53.8 · 95% CI -57.8 to -49.8Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis2.6 ± 1.6-54.9 ± 1.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -57.5 · 95% CI -61.5 to -53.5Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis2.6 ± 1.6-56.0 ± 1.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -58.6 · 95% CI -62.3 to -54.8Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis2.0 ± 1.3-39.5 ± 0.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -41.5 · 95% CI -44.6 to -38.4Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis-3.3 ± 1.5-54.6 ± 1.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -51.2 · 95% CI -54.9 to -47.6Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis-1.7 ± 1.4-56.3 ± 1.0
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -54.5 · 95% CI -57.9 to -51.1Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis-2.1 ± 1.1-41.1 ± 0.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -39.0 · 95% CI -41.7 to -36.4Alirocumab vs. Placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis

Calculated LDL-C goal was defined as: * \<100 mg/dL (2.59 mmol/L) for heFH or non-FH participants who had a history of documented congestive heart disease (CHD), or * \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases (ischemic stroke, peripheral artery disease, chronic kidney disease or diabetes) or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in imputation model.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis10.296.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 552.1 · 95% CI 105.6 to 2886.8Alirocumab vs. Placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis10.697.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 1367.8 · 95% CI 137.8 to 13578.3Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis2.5 ± 2.5-39.5 ± 1.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -42.0 · 95% CI -48.0 to -36.0Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis6.7 ± 3.7-15.3 ± 2.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -22.0 · 95% CI -30.9 to -13.1Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis2.1 ± 1.57.9 ± 1.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = 0.0020 (Threshold for significance ≤ 0.05.) · Ls mean difference: 5.8 · 95% CI 2.1 to 9.4Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo A1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis-2.6 ± 1.61.4 ± 1.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = 0.0382 (Threshold for significance ≤ 0.05.) · Ls mean difference: 4.0 · 95% CI 0.2 to 7.9Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis-0.5 ± 2.4-41.9 ± 1.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -41.4 · 95% CI -47.0 to -35.7Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis2.4 ± 3.7-13.1 ± 2.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Regression, Robust · p = 0.0007 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -15.5 · 95% CI -24.4 to -6.6Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis-1.8 ± 1.24.7 ± 0.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: 6.5 · 95% CI 3.7 to 9.3Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo A1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis-4.8 ± 1.11.5 ± 0.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 75 mg/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: 6.3 · 95% CI 3.6 to 9.0Alirocumab vs. Placebo
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
Percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis-3.6 ± 1.9-62.5 ± 1.4
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 52 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis
Percent changePlacebo Q2WAlirocumab 75 mg/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis-3.4 ± 1.7-64.6 ± 1.2

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 60 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—9/72 (12.5%)44/72 (61.1%)
Alirocumab 75 mg/ Up to 150 mg Q2W—10/143 (7%)97/143 (67.8%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlacebo Q2WAlirocumab 75 mg/ Up to 150 mg Q2W
Traumatic fractureInjury, poisoning and procedural complications2/721/143
Pyelonephritis acuteInfections and infestations1/721/143
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/720/143
Myocardial infarctionCardiac disorders1/721/143
Coronary artery stenosisCardiac disorders1/720/143
Intestinal obstructionGastrointestinal disorders1/720/143
SpondylolisthesisMusculoskeletal and connective tissue disorders1/720/143
Nephrotic syndromeRenal and urinary disorders1/720/143
ProstatitisReproductive system and breast disorders1/720/143
Medical device discomfortGeneral disorders1/720/143
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlacebo Q2WAlirocumab 75 mg/ Up to 150 mg Q2W
NasopharyngitisInfections and infestations26/7265/143
Back painMusculoskeletal and connective tissue disorders4/7218/143
Injection site reactionGeneral disorders3/7218/143
Diabetes mellitusMetabolism and nutrition disorders4/7212/143
InfluenzaInfections and infestations6/721/143
ArthralgiaMusculoskeletal and connective tissue disorders6/724/143
FallInjury, poisoning and procedural complications5/7211/143
Seasonal allergyImmune system disorders5/721/143
HypertensionVascular disorders5/729/143
PharyngitisInfections and infestations4/729/143

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Q2WAlirocumab 75 mg/Up to 150 mg Q2WTotal
Mean61.8 ± 9.060.3 ± 9.760.8 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WAlirocumab 75 mg/Up to 150 mg Q2WTotal
Female256085
Male4784131
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Placebo Q2WAlirocumab 75 mg/Up to 150 mg Q2WTotal
Mean141.6 ± 26.7140.9 ± 26.8141.2 ± 26.7
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Placebo Q2WAlirocumab 75 mg/Up to 150 mg Q2WTotal
Mean3.668 ± 0.6913.650 ± 0.6933.656 ± 0.691
08

Study locations

32 sites
  • Investigational Site Number 392016
    Adachi-Ku, Japan
  • Investigational Site Number 392029
    Adachi-Ku, Japan
  • Investigational Site Number 392024
    Aki-Gun, Japan
  • Investigational Site Number 392012
    Chuo-Ku, Japan
  • Investigational Site Number 392013
    Chuo-Ku, Japan
  • Investigational Site Number 392032
    Fukui-Shi, Japan
  • Investigational Site Number 392004
    Hakusan-Shi, Japan
  • Investigational Site Number 392028
    Kaga-Shi, Japan
  • Investigational Site Number 392002
    Kanazawa-Shi, Japan
  • Investigational Site Number 392005
    Kanazawa-Shi, Japan
  • Investigational Site Number 392023
    Kawanishi-Shi, Japan
  • Investigational Site Number 392009
    Kisarazu-Shi, Japan
  • Investigational Site Number 392026
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392003
    Komatsu-Shi, Japan
  • Investigational Site Number 392011
    Kuki-Shi, Japan
  • Investigational Site Number 392017
    Matsumoto-Shi, Japan
  • Investigational Site Number 392007
    Mito-Shi, Japan
  • Investigational Site Number 392006
    Moriya-Shi, Japan
  • Investigational Site Number 392018
    Nagoya-Shi, Japan
  • Investigational Site Number 392014
    Oota-Ku, Japan
  • Investigational Site Number 392019
    Osaka-Shi, Japan
  • Investigational Site Number 392020
    Osaka-Shi, Japan
  • Investigational Site Number 392022
    Osaka-Shi, Japan
  • Investigational Site Number 392030
    Osaka-Shi, Japan
  • Investigational Site Number 392027
    Oyabe-Shi, Japan
  • Investigational Site Number 392010
    Saitama-Shi, Japan
  • Investigational Site Number 392015
    Shinjuku-Ku, Japan
  • Investigational Site Number 392031
    Shizuoka-Shi, Japan
  • Investigational Site Number 392021
    Suita-Shi, Japan
  • Investigational Site Number 392025
    Takamatsu-Shi, Japan
  • Investigational Site Number 392008
    Tsuchiura-Shi, Japan
  • Investigational Site Number 392001
    Yamagata-Shi, Japan
09

References and documents

Publications

  • Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, Uno K, Baccara-Dinet MT, Nohara A. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial. Circ J. 2016 Aug 25;80(9):1980-7. doi: 10.1253/circj.CJ-16-0387. Epub 2016 Jul 22. Erratum In: Circ J. 2016;80(11):2414. doi: 10.1253/circj.CJ-66-0134. PubMed 27452202 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Jan 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2014
First posted
Apr 8, 2014
Start
Mar 2014
Primary completionActual
Jan 2015
CompletionActual
Sep 2015
Results first posted
Jan 29, 2016
Last update
Oct 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02107898
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
Mar 2014
Primary completion
Jan 2015
Completion
Sep 2015
Results posted
Jan 29, 2016
Last update
Oct 4, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion